Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / Farlow 6-marker panel for Lung Cancer

Farlow 6-marker panel for Lung Cancer

Basics

Attributes

QA State: Curated
Short Name:
HGNC Name:

This study aimed to develop a serum test that could be used to discern NSCLC patients from cancer-free controls and may provide a means to indicate who should have spiral CT done. A large number of potential tumor autoantibodies for NSCLC were identified and validated. The six-analyte blood test that resulted from this study (consisting of IMPDH, phosphoglycerate mutase, ubiquilin, Annexin I, Annexin II, and HSP70-9B) possessed excellent test performance characteristics when tested against our 196 patient cohort that was composed of four clinically distinct groups, with only 13 patients misclassified overall.

Panel Details

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Lung

Attributes

Phase: Two
QA State: Curated

Overview

This study aimed to develop a serum test that could be used to discern NSCLC patients from cancer-free controls and may provide a means to indicate who should have spiral CT done. A large number of potential tumor autoantibodies for NSCLC were identified and validated. The six-analyte blood test that resulted from this study (consisting of IMPDH, phosphoglycerate mutase, ubiquilin, Annexin I, Annexin II, and HSP70-9B) possessed excellent test performance characteristics when tested against our 196 patient cohort that was composed of four clinically distinct groups, with only 13 patients misclassified overall.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Organs

No associated resources found.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.
Announcement 09/14/2014

Thank you to everyone who helped make the 9th EDRN Scientific Workshop a success. We look forward to seeing everyone at the 28th EDRN Steering Committee Meeting from March 31-April 2, 2015, in Atlanta, GA.